These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 30483774)
1. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines. Aygun N; Altungoz O Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774 [TBL] [Abstract][Full Text] [Related]
2. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123 [TBL] [Abstract][Full Text] [Related]
4. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration. Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367 [TBL] [Abstract][Full Text] [Related]
5. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915 [TBL] [Abstract][Full Text] [Related]
6. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells. Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259 [TBL] [Abstract][Full Text] [Related]
7. MYCN‑amplified neuroblastoma cell‑derived exosomal miR‑17‑5p promotes proliferation and migration of non‑MYCN amplified cells. Chen W; Hao X; Yang B; Zhang Y; Sun L; Hua Y; Yang L; Yu J; Zhao J; Hou L; Lu H Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33537818 [TBL] [Abstract][Full Text] [Related]
8. microRNA‑202 suppresses MYCN expression under the control of E2F1 in the neuroblastoma cell line LAN‑5. Li YG; He JH; Yu L; Hang ZP; Li W; Shun WH; Huang GX Mol Med Rep; 2014 Feb; 9(2):541-6. PubMed ID: 24337320 [TBL] [Abstract][Full Text] [Related]
9. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma. Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952 [TBL] [Abstract][Full Text] [Related]
10. De Rosa P; Severi F; Zadran SK; Russo M; Aloisi S; Rigamonti A; Capranico G; Milazzo G; Perini G Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982482 [TBL] [Abstract][Full Text] [Related]
11. The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression. Zhao Z; Shelton SD; Oviedo A; Baker AL; Bryant CP; Omidvarnia S; Du L J Exp Clin Cancer Res; 2020 Feb; 39(1):41. PubMed ID: 32087738 [TBL] [Abstract][Full Text] [Related]
12. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients. Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155 [TBL] [Abstract][Full Text] [Related]
13. Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN. Teitz T; Wei T; Liu D; Valentine V; Valentine M; Grenet J; Lahti JM; Kidd VJ Oncogene; 2002 Mar; 21(12):1848-58. PubMed ID: 11896617 [TBL] [Abstract][Full Text] [Related]
14. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas. Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720 [TBL] [Abstract][Full Text] [Related]
15. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression. Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359 [TBL] [Abstract][Full Text] [Related]
16. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression. Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029 [TBL] [Abstract][Full Text] [Related]
17. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377 [TBL] [Abstract][Full Text] [Related]
18. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979 [TBL] [Abstract][Full Text] [Related]
19. Direct Targeting of Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073 [TBL] [Abstract][Full Text] [Related]
20. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells. Murakami-Tonami Y; Ikeda H; Yamagishi R; Inayoshi M; Inagaki S; Kishida S; Komata Y; Jan Koster ; Takeuchi I; Kondo Y; Maeda T; Sekido Y; Murakami H; Kadomatsu K Sci Rep; 2016 Aug; 6():31615. PubMed ID: 27539729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]